Imagine a world where the intricate dance between immune cells and cancer is illuminated in real-time. This is exactly what a researcher from Heriot-Watt University is set to achieve with a groundbreaking £2 million funding initiative aimed at developing cutting-edge quantum sensors. These innovative devices will enable scientists to closely observe how immune cells engage with cancer, shedding light on why some therapies succeed for certain individuals while others falter.
Dr. Aldona Mzyk is leading this pioneering project, which involves creating sensors so precise they can detect the signals emitted by a single electron. By capturing molecular changes in real-time, these ultra-sensitive instruments will provide unprecedented insights into how immune cells operate within the challenging environment of solid tumors. They will be able to track metabolic processes that lead to the exhaustion of cancer-fighting cells, identifying variations that are thousands of times smaller than a human hair's width.
This research addresses a significant challenge in the field of cancer immunotherapy. While CAR-T cell therapies have shown remarkable success in treating blood cancers, their effectiveness diminishes when tackling solid tumors. This is largely due to the presence of metabolites released by cancer tissue, which can disrupt the metabolism of engineered immune cells. Dr. Mzyk's quantum sensor platform aims to uncover the mechanisms behind this failure in real-time, allowing researchers to observe the chemical disruptions occurring within thousands of cells almost instantaneously.
Currently based at the Technical University of Denmark (DTU) in Copenhagen, Dr. Mzyk will soon join Heriot-Watt’s Institute of Photonics and Quantum Sciences. Here, she will spearhead the four-year Future Leaders Fellowship, which is funded by UK Research and Innovation. "Every minute, seventeen individuals succumb to cancer. To truly grasp why immune cells fail, we must monitor the free radicals that influence their metabolism — effectively eavesdropping on their interactions with cancer," Dr. Mzyk explains. "Quantum sensors provide us with the means to capture these rapid and minuscule signals with the needed precision."
This initiative merges quantum sensing with optical spectroscopy and microfluidics, resulting in a cohesive platform that could expedite the creation of personalized cancer treatments and offer early indicators of how well anti-cancer drugs are performing. Furthermore, it aligns with the UK's National Quantum Technology Programme and ongoing projects aimed at integrating clinical-grade quantum technologies into the National Health Service (NHS).
Professor Cristian Bonato, who leads the Nanoscale Quantum Sensing facility at Heriot-Watt, emphasized that this fellowship exemplifies a bold application of quantum technology that could revolutionize biomedical diagnostics. He noted that the university plays a vital role in several national quantum hubs dedicated to advancements in sensing, imaging, and healthcare.
Are you curious about how these quantum sensors might change the landscape of cancer treatment? What other applications do you think quantum technology could have in medicine? Share your thoughts in the comments!
